Targeting visceral obesity with inhibitors of aldosterone, neprilysin, and, particularly, sodium glucose transporter 2 (SGLT2) have been suggested for management of obesity-related HF, pending confirmation from ongoing large-scale trials [28]. The gene discussed is MME; the disease is obesity due to melanocortin 4 receptor deficiency.